2020
Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease
Zheng XZ, Qin XY, Chen SW, Wang P, Zhan Y, Zhong PP, Buza N, Jin YL, Wu BQ, Hui P. Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. Modern Pathology 2020, 33: 1979-1988. PMID: 32404958, DOI: 10.1038/s41379-020-0566-4.Peer-Reviewed Original ResearchConceptsNon-molar gestationsGestational trophoblastic diseaseTrophoblastic diseaseHigh riskGestational trophoblastic neoplasiaProducts of conceptionPatient demographicsClinical followClinical outcomesGynecology HospitalTrophoblastic neoplasiaBeijing ObstetricsFIGO criteriaChinese patientsClinical prognosisPatient managementLarge cohortGestationMolar gestationDiseaseGenetic abnormalitiesChromosomal monosomyChromosomal aneuploidyHydatidiformUniparental disomy
2019
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma
Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.Peer-Reviewed Original ResearchConceptsLow-grade endometrial stromal sarcomaRecurrence-free survivalStage I patientsEndometrial stromal sarcomaAromatase inhibitorsI patientsStage IIStromal sarcomaAdvanced low-grade endometrial stromal sarcomaMean recurrence-free survivalLonger recurrence-free survivalAdjuvant hormonal therapyMedian followProgestin groupUnderwent hysterectomyHormonal therapyDisease recurrenceSide effectsPatientsStage IProgestinsMonthsSarcomaDiseaseTreatment
2011
Gestational Choriocarcinoma
Hui P. Gestational Choriocarcinoma. Current Clinical Pathology 2011, 127-137. DOI: 10.1007/978-1-61779-394-3_8.Peer-Reviewed Original ResearchGestational choriocarcinomaMalignant tumorsMethotrexate-based chemotherapyMortality of patientsDecidua of pregnancyHematogenous spreadCure rateFatal malignancyTrophoblastic diseaseChemotherapy managementAggressive formChoriocarcinomaChorial villiTumorsTumor cellsSarcomaDiseaseChemotherapyPatientsPregnancyDramatic decreaseMalignancyMortalityPlacentaDeciduaMinimal Uterine Serous Carcinoma With Extrauterine Spread
Flynn C, Hui P. Minimal Uterine Serous Carcinoma With Extrauterine Spread. Advances In Anatomic Pathology 2011, 16: 104-107. DOI: 10.1097/pcr.0b013e31821734fe.Peer-Reviewed Original ResearchMinimal uterine serous carcinomaUterine serous carcinomaSerous carcinomaEndometrial polypsSerous endometrial intraepithelial carcinomaEndometrial intraepithelial carcinomaExtrauterine diseaseConventional serous carcinomasExtrauterine spreadAbdominal carcinomatosisIntraepithelial carcinomaMüllerian carcinomasImmunohistochemical profileMutant p53 proteinPatient's diseaseCarcinomaDiseaseP53 proteinPolypsPresumed originCarcinomatosisPostmenopausalPatientsUterusTumors
2010
Gestational Trophoblastic Disease
Chhieng D, Hui P. Gestational Trophoblastic Disease. Current Clinical Pathology 2010, 131-138. DOI: 10.1007/978-1-60761-164-6_8.Peer-Reviewed Original ResearchHER-2/NEU overexpression in vulvar Paget disease: the Yale experience
Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal Of Clinical Pathology 2010, 63: 544. PMID: 20418225, DOI: 10.1136/jcp.2010.077446.Peer-Reviewed Original ResearchConceptsVulvar Paget's diseasePaget's diseaseNeu overexpressionOutcome dataHER-2/neu expressionHER-2/neuEfficacy of trastuzumabExtensive reconstructive proceduresHigh recurrence rateMedical record searchInteresting treatment optionSurgical treatmentRecurrence rateTreatment optionsNeu expressionClinical trialsReconstructive proceduresTissue microarrayPatientsRecord searchTumor samplesYale experienceDiseaseNeuStaining results